Florida State University Research Foundation, Inc.

Emory University

Other

North Carolina State University

University of Kansas

Children's Healthcare of Atlanta, Inc.

University of Delhi

Shandong University

Children's Heatlhcare of Atlanta

Binghe Wang

Xingyue Ji

Chaofeng Dai

Yueqin Zheng

Krishna Damera

Zhixiang Pan

Nanting Ni

Alexander Draganov

Erwin Van Meir

Didier Merlin

Weixuan Chen

Emilie Viennois

Hanjing Peng

Minyong Li

Xiaochuan Yang

Guojing Sun

Danzhu Wang

Hao Fang

Valentino J Stella

Zhen Qiu Huang

Teruna J Siahaan

Shilong Zheng

Ronald T Borchardt

Chunhao Yang

Charles D Derby

Phang C Tai

Yong Chu

Diwan S Rawat

Nitin Kumar

Sunny Manohar

Junfeng Wang

Brent Weston

Phang-Cheng Tai

Ying-Ju Ritter

Jianmei Cui

Arpana S Chaudhary

Lifang Wang

Ko-Chun Ko

Kaili Ji

Michiya Kamio

Bingchen Yu

Jalisa Holmes Ferguson

Na Lin

Chung-Dar Lu

Han-Ting Chou

Stefan Kaluz

Yunfeng Cheng

Xingming Gao

Wenqian Yang

Jun Yan

Muxiang Zhou

Robert Emuobonuvie Aghoghovbia

Lubing Gu

Ladie Kimberly C De La Cruz

Sanjeev Gangwar

Xiaoxiao Yang

Jinshan Jin

Ladie Kimberly De La Cruz

Yinghsin Hsieh

Wen Fang Xu

Charles Derby

Pang C Tai

Ladie Kim De La Cruz

Fang Hoa

Yan Ling Li

The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.

Carbon monoxide prodrugs for the treatment of medical disorders

The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs.

Carbon monoxide-releasing molecules triggered by physiological stimuli

Disclosed herein is a chemical delivery system having: i) a cargo compound comprising a first reactive moiety covalently bonded to a first enrichment moiety and a tethered cargo moiety, wherein the first reactive moiety is bonded to the tethered cargo moiety via a cleavable linker; and ii) a trigger compound comprising a second reactive moiety covalently bonded to a second enrichment moiety and a cargo-releasing moiety. The first enrichment moiety and the second enrichment moiety cause an increase in concentration of the cargo compound and the concentration of the trigger compound at a target site, causing a bimolecular reaction between the first reactive moiety and the second reactive moiety to form a cyclization precursor compound. The cargo moiety is then released from the cyclization precursor compound in a unimolecular cyclization reaction. Methods for treating conditions such as cancer, inflammatory conditions, and infections with the chemical delivery systems are also described.

Enrichment-triggered chemical delivery system

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37&#xb0; C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

Carbon-monoxide-releasing molecules and therapeutic applications thereof

The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs. The compounds disclosed herein contain a cyclopentadienone moiety, a non-reactive dienophile, and an enzyme-cleavable tethering moiety connecting the cyclopentadienone moiety to the non-reactive dienophile. Cleavage of the enzyme-cleavable tethering moiety results in conversion of the non-reactive dienophile to a reactive dienophile.

Enzyme-triggered carbon monoxide releasing molecules

This disclosure relates to benzhydrol derivatives for managing conditions related to the Hypoxia Inducible Factor (HIF) pathway such as uses in treating cancer. In certain embodiment, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiment, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof.

Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors

Carbon monoxide-releasing molecules for therapeutic applications and methods for the preparation and use thereof

The present invention provides methods of forming hydrogen sulfide. The methods include contacting a precursor compound with an unmasking agent; wherein the precursor compound comprises a hydrogen sulfide releasing moiety and a masked nucleophile; and wherein the contacting is conducted under conditions sufficient for cyclization of the precursor compound via lactone or lactam formation; thereby releasing hydrogen sulfide from the precursor compound. Hydrogen sulfide precursor compounds according to Formula I are also described, as well as methods for treating diseases and conditions using hydrogen sulfide precursors. 

Hydrogen sulfide precursors and conjugates thereof

Rhein analogues that exhibit anti-proliferative activity, particular against cancer cells, are described herein. In some embodiments, the compounds contain a flat or planar ring system. Such rings system by facilitate non-covalent binding of the compounds to the DNA complex, such as by intercalation. In some embodiment, the compounds contain a flat or planar ring system as described above and one or more substituents which are alkylating moieties, electrophilic groups or Michael acceptors or groups which contain one or more alkylating moieties, electrophilic groups and/or Michael acceptors. The compounds described herein can also contain one more functional groups to improve the solubility of the compounds.

Anthraquinone analogs and methods of making and using thereof

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37 C and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof

Inhibitors of SecA, and methods of making and using thereof, are described herein. The compounds described herein can be used to treat or prevent microbial infections, such as bacterial infections.

SecA inhibitors and methods of making and using thereof

Compounds having Formula I or II, and methods of making and using thereof, are described herein: 

Curcumin analogs and methods of making and using thereof

Disclosed are conjugates that can bind to one or more site on cancer cell surface, for example, surface proteins, compound specific receptors and carbohydrates that comprise the surface of specific cell types. The disclosed conjugates can thereby serve as indicators identifying the presence of cancerous tissue.

Cellular recognition conjugates and methods of use for the histological analysis of cancer tissue using MALDI-MS imaging

Disclosed herein are antimicrobial compositions, kits, and articles of manufacture. Further disclosed herein are methods for treating surfaces, including tissue, inter alia, wounds, with the disclosed compositions.

Antimicrobial compositions and methods of use

Selective chemosensing agents for hydrogen sulfide are provided. The chemosensing agents can act fast under mild conditions, are chemically stable for long-term storage, are sensitive for detection under near physiological conditions, show a linear concentration-signal relationship within physiologically relevant hydrogen sulfide concentration ranges for easy quantitation, show minimal or no interference by other anions in the blood, and are functional in aqueous solutions and blood plasma.

Chemosensors for hydrogen sulfide

Growing community of inventors

Marietta, GA, United States of America

Binghe Wang